AZN
AstraZenecaFNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Positive late-stage readouts and a favorable FY2025 beat lead to multiple expansion and re-rating toward the upper analyst range within 12 months.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Late-stage clinical trial failure or delay
Momentum
17
Value
63
Sentiment
7
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $97.65 · Bull $123.69 · Bear $79.98
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-24 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $216.42
Why
Momentum17 · Δ7d -9.5
Value63 · Δ7d -0.1
Sentiment7 · Δ7d -0.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
17
26% active weight
Current posture
7d trendFlat
Δ7d
-9.5
Δ21d
-14.6
Value
63
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.7
Sentiment
7
34% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+4.6
Why this grade
Composite grade F. Momentum 17.0 / Value 63.4 / Sentiment 7.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$264.69B
Beta
0.86
Shares Out
1.55B
P/E (TTM)
29.9
P/S (TTM)
4.81
P/FCF (TTM)
60.77
Rev YoY
+12.5%
EPS YoY
+5.7%
Gross Margin
+74.3%
Op Margin
+22.0%
Net Debt
$23.88B
Current Ratio
0.91
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology